The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
Abstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14603 |
| _version_ | 1798033005662437376 |
|---|---|
| author | Yu Feng Liling Huang Haohua Zhu Le Tang Xingsheng Hu Yuankai Shi |
| author_facet | Yu Feng Liling Huang Haohua Zhu Le Tang Xingsheng Hu Yuankai Shi |
| author_sort | Yu Feng |
| collection | DOAJ |
| description | Abstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents. Results A total of 54 patients with NSCLC were enrolled into the study. Twelve (22.2%) who received a combination of antiangiogenic agents, when there was a trend of osimertinib resistance but did not reach imageology progressive disease (PD), were assigned to Group A, with a median overall survival (OS) and progression‐free survival (PFS) of 48.0 (95% CI, not reached) and 21.0 (95% CI: 16.7–25.3) months, respectively. Thirty (55.6%) who received a combination of antiangiogenic agents when there was imageology PD during treatment with osimertinib were assigned to Group B, with a median OS and PFS of 31.8 (95% CI: 26.6–37.1) and 9.2 (95% CI: 5.9–12.6) months, respectively. Twelve (22.2%) who received a combination of antiangiogenic agents at the initial treatment with osimertinib were assigned to Group C, with a median OS and PFS of 28.5 (95% CI: 15.2–41.8) and 15.3 (95% CI: 7.9–22.7) months, respectively. Patients in Group A achieved a significant prolonged median PFS (p < 0.001) compared with Groups B and C. Absence of epidermal growth factor receptor (EGFR) T790M mutations (p = 0.043; hazard ratio [HR] = 2.124, 95% CI: 1.023–4.413) and no previous antiangiogenic agent application (p = 0.012; HR = 0.362, 95% CI: 0.163–0.863) were the independent prognostic factors of OS. Conclusion The well‐timed action to combine antiangiogenic agents was when there was a trend of osimertinib resistance. The absence of EGFR T790M mutations and previous use of antiangiogenic agents were poor prognostic factors. |
| first_indexed | 2024-04-11T20:23:16Z |
| format | Article |
| id | doaj.art-f759123424b5420296231fcd9fc8edd7 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-11T20:23:16Z |
| publishDate | 2022-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-f759123424b5420296231fcd9fc8edd72022-12-22T04:04:46ZengWileyThoracic Cancer1759-77061759-77142022-09-0113182641264910.1111/1759-7714.14603The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world studyYu Feng0Liling Huang1Haohua Zhu2Le Tang3Xingsheng Hu4Yuankai Shi5Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing ChinaAbstract Background Real‐world application of osimertinib with antiangiogenic agents in non‐small cell lung cancer (NSCLC) is common, but the efficacy data are rarely reported. Methods To obtain an objective efficacy report of different real‐world treatment models of osimertinib and antiangiogenic agents. Results A total of 54 patients with NSCLC were enrolled into the study. Twelve (22.2%) who received a combination of antiangiogenic agents, when there was a trend of osimertinib resistance but did not reach imageology progressive disease (PD), were assigned to Group A, with a median overall survival (OS) and progression‐free survival (PFS) of 48.0 (95% CI, not reached) and 21.0 (95% CI: 16.7–25.3) months, respectively. Thirty (55.6%) who received a combination of antiangiogenic agents when there was imageology PD during treatment with osimertinib were assigned to Group B, with a median OS and PFS of 31.8 (95% CI: 26.6–37.1) and 9.2 (95% CI: 5.9–12.6) months, respectively. Twelve (22.2%) who received a combination of antiangiogenic agents at the initial treatment with osimertinib were assigned to Group C, with a median OS and PFS of 28.5 (95% CI: 15.2–41.8) and 15.3 (95% CI: 7.9–22.7) months, respectively. Patients in Group A achieved a significant prolonged median PFS (p < 0.001) compared with Groups B and C. Absence of epidermal growth factor receptor (EGFR) T790M mutations (p = 0.043; hazard ratio [HR] = 2.124, 95% CI: 1.023–4.413) and no previous antiangiogenic agent application (p = 0.012; HR = 0.362, 95% CI: 0.163–0.863) were the independent prognostic factors of OS. Conclusion The well‐timed action to combine antiangiogenic agents was when there was a trend of osimertinib resistance. The absence of EGFR T790M mutations and previous use of antiangiogenic agents were poor prognostic factors.https://doi.org/10.1111/1759-7714.14603antiangiogenic agentsnon‐small cell lung cancerosimertinibresistance |
| spellingShingle | Yu Feng Liling Huang Haohua Zhu Le Tang Xingsheng Hu Yuankai Shi The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study Thoracic Cancer antiangiogenic agents non‐small cell lung cancer osimertinib resistance |
| title | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
| title_full | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
| title_fullStr | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
| title_full_unstemmed | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
| title_short | The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study |
| title_sort | exploration of three different treatment models of osimertinib plus antiangiogenic agents in non small cell lung cancer a real world study |
| topic | antiangiogenic agents non‐small cell lung cancer osimertinib resistance |
| url | https://doi.org/10.1111/1759-7714.14603 |
| work_keys_str_mv | AT yufeng theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT lilinghuang theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT haohuazhu theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT letang theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT xingshenghu theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT yuankaishi theexplorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT yufeng explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT lilinghuang explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT haohuazhu explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT letang explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT xingshenghu explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy AT yuankaishi explorationofthreedifferenttreatmentmodelsofosimertinibplusantiangiogenicagentsinnonsmallcelllungcancerarealworldstudy |